MRNA stock forecast: what analysts expect
Wall Street analysts covering Moderna, Inc. currently rate the stock a Hold on average, with a mean 12-month price target of $50.84 — -20.1% versus the last price of $63.67. Targets reflect analyst opinion, not a guarantee.
MRNA historical returns
Based on monthly dividend-adjusted prices. See the full breakdown on what if you had invested in MRNA.
MRNA annual returns by year
Congress trading in MRNA
4 members of Congress have disclosed trading MRNA — 2 purchases and 10 sales worth an estimated $134,502. Most recent disclosure: Apr 8, 2025.
See who in Congress traded MRNA →Insider activity in MRNA
MRNA's own executives and directors have made 0 open-market purchases ($0) and 9 sales ($38.2M) in the last 90 days, per SEC Form 4 filings. Most recent: Aug 5, 2026.
| Aug 5, 2026 | Bancel Stephane | Chief Executive Officer | Sell | $8.3M |
| Aug 5, 2026 | Bancel Stephane | Chief Executive Officer | Sell | $7.1M |
| Aug 5, 2026 | Bancel Stephane | Chief Executive Officer | Sell | $2.3M |
| Aug 5, 2026 | Bancel Stephane | Chief Executive Officer | Sell | $11.0M |
| Jul 15, 2026 | Hoge Stephen | President | Sell | $3.6M |
About Moderna, Inc.
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
MRNA Key Statistics
MRNA in plain English
- ROE (-39.00%) — how efficiently the company turns shareholders' money into profit. Negative means it's currently losing money on that equity.
- Profit margin (-141.43%) — of every $1 in sales, this is what's left as profit after all costs.
- Dividend — MRNA doesn't pay a meaningful dividend; the return here comes from the share price, not cash payouts.
MRNA stock: frequently asked questions
What is Moderna, Inc.'s stock price today?
Moderna, Inc. (MRNA) last traded at $63.67 on the NASDAQ. Over the past 52 weeks the stock has traded between $22.28 and $85.60.
Is MRNA stock a buy or a sell?
Wall Street analysts' consensus rating on MRNA is "Hold", with an average 12-month price target of $50.84 — about -20.1% versus the current price of $63.67. Analyst targets are opinions, not guarantees; always do your own research.
Does MRNA pay a dividend?
No — Moderna, Inc. does not currently pay a meaningful dividend. Returns for shareholders come from changes in the share price.
Do members of Congress trade MRNA stock?
Yes — 4 members of Congress have disclosed trades in MRNA under the STOCK Act, totaling 2 purchases and 10 sales worth an estimated $134,502.
What is Moderna, Inc.'s ticker symbol?
Moderna, Inc. trades under the ticker symbol MRNA on the NASDAQ.
Compare MRNA with peers
Data last refreshed from public sources. Figures may be delayed. Not investment advice.